Celcuity Reports Positive Results from Phase 3 Study of Gedatolisib

Celcuity announced positive results from the Phase 3 clinical trial of its drug gedatolisib, developed for the treatment of breast cancer. The company stated that these results represent a significant milestone in terms of the drug's efficacy and safety. The Phase 3 study demonstrated that gedatolisib provided better outcomes compared to current standard treatments in a specific subtype of breast cancer. Celcuity management indicated that these data could accelerate the drug's regulatory approval process. The company plans to initiate discussions with regulatory authorities in the coming period and file a marketing authorization application for gedatolisib. This development may have a positive impact on Celcuity's stock performance. This is not investment advice.